by NavigoProteins | Apr 1, 2025 | Press
HALLE, Germany and MOL, Belgium, 01.04.2025 Navigo Proteins GmbH, a leader in precision medicine and next-generation radiotheranostics, today announced a strategic research collaboration with SCK CEN, the Belgian Nuclear Research Centre. This partnership will focus on...
by NavigoProteins | Dec 12, 2024 | Press
HALLE and HEIDELBERG, Germany, December 12, 2024 Navigo Proteins GmbH, an innovator developing next-generation targeted radiotheranostics, and VERAXA Biotech AG, an emerging leader in designing novel cancer therapies, announced today the initiation of a research...
by NavigoProteins | Sep 6, 2023 | Press
Halle (Saale), Germany and Barcelona, Spain, September 06, 2023 – We are excited to announce a pioneering partnership between Nostrum Biodiscovery, a frontrunner in computational molecular engineering services, and Navigo Proteins, an innovator developing next...
by NavigoProteins | Sep 26, 2022 | Press
The Precision X affinity ligand will enable an innovative affinity chromatography step for the efficient purification of the non-Fc fusion protein allowing a mAb-like process architecture Halle/Saale, September 26, 2022 – Navigo Proteins GmbH (“Navigo”), a premier...
by NavigoProteins | Jul 20, 2022 | Press
Affinity resin enables efficient capture of Ferritin from blood fractions despite low serum concentrations Halle/Saale, Germany, July 20th, 2022. Navigo Proteins GmbH (“Navigo”), a premier protein engineering company and developer of affinity ligands for custom...
by USER_1 | Jun 2, 2022 | Press
Alternative purification strategy enables platform resin use across a multitude of products. Halle/Saale, Germany, June 2nd, 2022. Navigo Proteins GmbH (“Navigo”), a premier protein engineering company and developer of affinity ligands for custom chromatography...
Recent Comments